New shot could ease daily struggles for myasthenia gravis patients
NCT ID NCT06447597
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new drug called B007 in 104 people with generalized myasthenia gravis, a condition that causes muscle weakness. Participants receive either B007 or a placebo as a shot under the skin twice a month. The goal is to see if B007 improves daily activities, like walking or eating, better than a placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
B007 (a drug given as a shot under the skin)
What this could lead to
If it works, this could offer a new treatment option to help people with generalized myasthenia gravis manage their symptoms better.
What could go wrong
This is an early-to-mid stage trial with only 104 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED MYASTHENIA GRAVIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Hospital of Zunyi Medical College
RECRUITINGZunyi, China
Contact
-
First People's Hospital of Yunnan Province
RECRUITINGKunming, China
Contact
-
Huashan Hospital, Fudan University
RECRUITINGShanghai, China
Contact
-
Jiangxi Provincial People's Hospital
RECRUITINGNanchang, China
Contact
-
Nanfang Hospital, Southern Medical University
RECRUITINGGuangzhou, China
Contact
-
Peking University First Hospital
RECRUITINGBeijing, China
Contact
-
Renmin Hospital of Wuhan University
RECRUITINGWuhan, China
Contact
-
Shandong Provincial Qianfoshan Hospital
RECRUITINGJinan, China
Contact
-
Shandong University Cheeloo College of Medicine
RECRUITINGJinan, China
Contact
-
Shandong University Cheeloo College of Medicine
RECRUITINGQingdao, China
Contact
-
Shenzhen Hospital of University of Hong Kong
RECRUITINGShenzhen, China
Contact
-
Sichuan Provincial People's Hospital
RECRUITINGChengdu, China
Contact
-
Tangdu Hospital
RECRUITINGXi'an, China
Contact
-
The First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, China
Contact
-
The First Bethune Hospital of Jilin University
RECRUITINGChangchun, China
Contact
-
The Second Affiliated Hospital of Nanchang University
RECRUITINGNanchang, China
Contact
-
Tongji Medical College of HUST
RECRUITINGWuhan, China
Contact
-
Xiangya Hospital Central South University
RECRUITINGChangsha, China
Contact